Clinical Trials Logo

Clinical Trial Summary

This study will determine if a combination of 3 drugs used to treat the infection that cause lymphatic filariasis (LF) due to Wuchereria bancrofti infection are more effective in killing or sterilizing the adult worms compared to just 2 of the 3 drugs that usually given to treat this infection. The three drugs used together are called albendazole (ALB), ivermectin (IVM) and diethylcarbamazine (DEC). The usual treatment in Papua New Guinea (PNG) for lymphatic filariasis are DEC and ALB. A combination of these 3 drugs has not been previously used to treat LF.


Clinical Trial Description

This study will determine whether a single dose of the triple drug regimen of DEC/Iver/Alb is non-inferior to annual treatments with DEC/Alb in inducing sustained clearance of Mf in LF infected subjects (>50 Mf/ml) at 36 months post-treatment. This study also tests the hypothesis that single dose of triple drug is super in sustained clearance of microfilariae compared to single dose of DEC/ALB.

There will be 3 treatment arms as follows:

1. The comparator (standard treatment) DEC 6 mg/kg + Alb 400 mg administered annually (at 0, 12, and 24 months).

2. DEC 6 mg/kg + Alb 400 mg given once

3. DEC 6 mg/kg + Alb 400 mg + Iver 200 µg/kg administered once only at the beginning of the RCT (0 month). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01975441
Study type Interventional
Source University Hospitals Cleveland Medical Center
Contact
Status Completed
Phase Phase 2
Start date May 2014
Completion date June 2018

See also
  Status Clinical Trial Phase
Completed NCT00375583 - Effect of Albendazole Dose on Clearance of Filarial Worms Phase 2
Completed NCT03664063 - PK PD Study of IDA and Azithromycin for NTDs ( ComboNTDs ) Phase 2
Recruiting NCT04844905 - Adjunctive Ivermectin Mass Drug Administration for Malaria Control Phase 3
Completed NCT01629771 - Disability and Quality of Life in Patients With Lymphatic Filariasis in Rural Southern India N/A
Completed NCT01905423 - Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis
Completed NCT02784743 - Impact of Albendazole -Ivermectin on Wuchereria Bancrofti in Mali Phase 4
Completed NCT03036059 - Twice Yearly Treatment for the Control of LF Phase 4
Completed NCT01905436 - Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia
Completed NCT02509481 - Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study Phase 2/Phase 3
Completed NCT03268252 - Optimization of MDA With Existing Drug Regimens for LF: Monitoring Efficacy of Ongoing Treatment Programs in PNG
Completed NCT02927496 - A 24 Month Study, to Compare the Efficacy of Doxycycline vs. Placebo for Improving Filarial Lymphedema in Mali Phase 3
Completed NCT02899936 - Death to Onchocerciasis and Lymphatic Filariasis (DOLF) Triple Drug Therapy for Lymphatic Filariasis N/A
Completed NCT00511004 - Effect of Albendazole Dose on Treatment of Lymphatic Filariasis Phase 2
Active, not recruiting NCT04258670 - Spontaneous Antigenemia in Loiasis
Completed NCT02974049 - Lymphatic Filariasis (LF) in Ivory Coast N/A
Terminated NCT01213576 - Efficacy of Higher Albendazole and Ivermectin Doses on Wuchereria Bancrofti Microfilarial Clearance in Malawi N/A
Completed NCT02929121 - A 24 Month Study to Compare Efficacy of Doxycycline vs Placebo for Improving Filarial Lymphedema in India Phase 3
Completed NCT00339417 - Effect of Albendazole Dose on Clearance of Filarial Worms Phase 2
Withdrawn NCT01903057 - Safety Study of Combined Azithromycin, Ivermectin and Albendazole for Trachoma and Lymphatic Filariasis Phase 4
Completed NCT02032043 - Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast)